Patent US4385178A successfully refreshed from Google Patents.
US4385178A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for producing 7-(substituted)amino-3-substituted thiomethyl cephem carboxylic acids
Assignee: Toyama Chemical Co Ltd
•
Filing: 1981-12-17
•
Granted: 1983-05-24
•
Expires: 2001-12-17
Abstract
Abstract This disclosure relates to a novel process for producing 7-(substituted)amino-3-substituted thiomethyl cephem carboxylic acids which are intermediate products of cephalosporins being valuable antibacterial compounds for use in mammals including man.
Inventors
- 👤 Isamu Saikawa
- 👤 Shuntaro Takano
- 👤 Kaishu Momonoi
- 👤 Isamu Takakura
- 👤 Seietsu Kuroda
- 👤 Kiyoshi Tanaka
- 👤 Kenshin Hayashi
- 👤 Bunei Nagahashi
- 👤 Chiaki Kutani
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 01:29
CPC Classifications
C; C07; C07D; C07D501/00; C07D501/02; C07D501/04
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
239 words
A process for producing a 7-(substituted)-amino-3-substituted thiomethyl cephem carboxylic acid represented by the formula: ##STR17## wherein R 1 is a hydrogen atom; R 2 is an amino group; and R 8 is a moiety of a compound of the formula HSR 8 wherein SR 8 is a conventional 3-position cephalosporin thio substituent wherein R 8 is an unsubstituted or substituted ring carbon containing heterocyclic group, or said compound (I) in which the carboxyl group is protected by a conventional cephalosporin carboxy protecting group or a conventional cephalosporin salt thereof, which comprises reacting a cephalosporanic acid represented by the formula: ##STR18## wherein R 1 and R 2 have the same meanings as defined above; X is carboxylic acyloxy or carbamoyloxy group or one of said groups substituted by a conventional cephalosporin substituent; >Y is >S or>S→O; or said compound (II) in which the carboxyl group is protected by a conventional cephalosporin carboxy protective group or a conventional cephalosporin salt thereof, with a thiol compound represented by the formula: R.sup.8 --SH (III) wherein R 8 has the same meaning as defined above, or a salt thereof with a compound forming a conventional cephalosporin salt, in a non-aqueous organic solvent at a temperature of -20° to 80° C. in the presence of boron trifluoride or a complex compound thereof which acts as boron trifluoride, the boron and the fluorine bonded to boron in said complex compound being present as BF 3 .
Claim 2
Dependent Claim
239 words
A process for producing a 7-(substituted)-amino-3-substituted thiomethyl cephem carboxylic acid represented by the formula: ##STR17## wherein R 1 is a hydrogen atom; R 2 is an amino group; and R 8 is a moiety of a compound of the formula HSR 8 wherein SR 8 is a conventional 3-position cephalosporin thio substituent wherein R 8 is an unsubstituted or substituted ring carbon containing heterocyclic group, or said compound (I) in which the carboxyl group is protected by a conventional cephalosporin carboxy protecting group or a conventional cephalosporin salt thereof, which comprises reacting a cephalosporanic acid represented by the formula: ##STR18## wherein R 1 and R 2 have the same meanings as defined above; X is carboxylic acyloxy or carbamoyloxy group or one of said groups substituted by a conventional cephalosporin substituent; >Y is >S or>S→O; or said compound (II) in which the carboxyl group is protected by a conventional cephalosporin carboxy protective group or a conventional cephalosporin salt thereof, with a thiol compound represented by the formula: R.sup.8 --SH (III) wherein R 8 has the same meaning as defined above, or a salt thereof with a compound forming a conventional cephalosporin salt, in a non-aqueous organic solvent at a temperature of -20° to 80° C. in the presence of boron trifluoride or a complex compound thereof which acts as boron trifluoride, the boron and the fluorine bonded to boron in said complex compound being present as BF 3 .
Claim 3
Dependent Claim
50 words
The process according to claim 1 wherein R 8 is 5-(1,2,3,4-tetrazolyl), 5-(1-methyl-1,2,3,4-tetrazolyl), 5-(1-ethyl-1,2,3,4-tetrazolyl), 5-(1-sulfomethyl-1,2,3,4-tetrazolyl), 5-(1-carboxymethyl- 1,2,3,4-tetrazolyl), 5-[2-(2-carbamoylethyl)-1,2,3,4-tetrazolyl], 5-[1-(2-sulfamoylethyl)-1,2,3,4-tetrazolyl], 5-[1-(2-N,N-dimethylaminoethyl)-1,2,3,4-tetrazolyl], 5-[2-(2-N,N-dimethylaminoethyl)-1,2,3,4-tetrazolyl], 5-[1-(2-N,N-diethylaminoethyl)-1,2,3,4-tetrazolyl], 5-(1-methoxycarbonylmethyl-1,2,3,4-tetrazolyl), 5-(1-carbamoylmethyl-1,2,3,4-tetrazolyl), 5-[1-(2-hydroxyethyl)-1,2,3,4-tetrazolyl], 5-[1-(2-aminoethyl)-1,2,3,4-tetrazolyl], 5-(1-phenyl-1,2,3,4-tetrazolyl), 5-(1-vinyl-1,2,3,4-tetrazolyl), 2-(1,3,4-thiadiazolyl), 2-(5-methyl-1,3,4-thiadiazolyl), 2-(5-ethyl-1,3,4-thiadiazolyl), 2-(5-amino-1,3,4-thiadiazolyl), 2-(5-phenyl-1,3,4-thiadiazolyl), 5-(3-methyl-1,2,4-thiadiazolyl), 2-(5-carboxymethyl-1,3,4-thiadiazolyl), 5-(1,2,3-triazolyl), 2-(1-methyl-1,3,4-triazolyl), 2-(5-methyl-1,3,4-triazolyl), 2-(1,5-dimethyl-1,3,4-triazolyl), 4-(5-ethoxycarbonyl-1,2,3-triazolyl), 4-(5-carboxy-1,2,3-triazolyl), 2-(5-ethoxycarbonylmethyl-1,3,4-triazolyl), benzoxazolyl, 2-(benzimidazolyl), 2-(5-methyl-1,3,4-oxadiazolyl), 2-(5-methyl-1,3-thiazolyl), 2-(5-methyl-1,3-oxazolyl), 2-(1,3-thiazolyl), 5-(1,2,3,4-thiatriazolyl) or 2-(imidazolyl).
Claim 4
Dependent Claim
22 words
The process according to claim 1, wherein R 8 is 2-(1,3,4-thiadiazolyl), 2-(5-methyl-1,3,4-thiadiazolyl), 2-(1-methyl-1,3,4-triazolyl), 5-(1,2,3,4-tetrazolyl), 5-(1-methyl-1,2,3,4-tetrazolyl), 5-(1-carbamoylmethyl-1,2,3,4-tetrazolyl), 5-[1-(2-hydroxyethyl)-1,2,3,4-tetrazolyl], 5-(1vinyl-1,2,3,4-tetrazolyl), 5-[1-(2-aminoethyl)-1,2,3,4-tetrazolyl], 5-[2-(2-N,N-dimethylaminoethyl)-1,2,3,4-tetrazolyl] or 5-[1-(2-N,N-dimethylaminoethyl)-1,2,3,4-tetrazolyl].
Claim 5
Dependent Claim
24 words
The process according to claim 3, wherein the objective compound is a compound represented by the general formula (I) set forth in claim 1.
Claim 6
Dependent Claim
34 words
The process according to claim 4, wherein a compound represented by the general formula (II) set forth in claim 1 wherein >Y is >S and X is acetoxy is used as the starting compound.
Claim 7
Dependent Claim
11 words
The process according to claim 5, wherein R 8 is 5-(1-methyl-1,2,3,4-tetrazolyl).
References Cited (Backward Citations)
DE1795484U
Cited
BE650445A
Cited
BE650444A
Cited
US3261832A
Cited
US3516997A
Cited
DE2065621A1
Cited
US3833572A
Cited
US3872115A
Cited
GB1400804A
Cited
US3840531A
Cited
DE2332045A1
Cited
US4014874A
Cited
DE2530622A1
Cited
DE2537974A1
Cited
US4317907A
Cited
US4144391A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-05-23 | 1986-11-22 | 1987-05-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-05-23 | 1990-11-22 | 1991-05-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-05-23 | 1994-11-22 | 1995-05-24 | $7700.00 | Window Closed / Lapsed |